Results 171 to 180 of about 60,573 (236)

Development and Validation of RP-UPLC Method for Simultaneous Determination of Lamivudine and Dolutegravir in Combined Dosage Forms

Poluri Lakshmi Anusha*, Dr. M. Ajitha
openalex   +1 more source

Long-Term Outcomes of Patients Who Receive a Liver Transplant for Hepatitis B With Limited Use of Hepatitis B Immunoglobulin. [PDF]

Clin Transplant
Roldan GA, Loon E, Lake J, Lim N.
europepmc   +1 more source

Assessing the preparedness of primary healthcare facilities for the implementation of universal test and treat in uThukela District, South Africa: a cross-sectional study. [PDF]

BMJ Public Health
Turawa E, Basera W, Hlongwa M, Mathole T, Bradshaw D, Nicol E.   +5 more
europepmc   +1 more source

SIMULTANEOUS QUANTIFICATION OF LAMIVUDINE, ZIDOVUDINE, LOPINAVIR AND RITONAVIR BY UPLC-ESI-MS-MS IN PLASMA AND BREAST MILK OF HIV-PREGNANT WOMEN FOR THERAPEUTIC DRUG MONITORING

, 2018
Jessica Hernández‐Pineda, Alicia Ramírez-Ramírez, Noemí Guadalupe Plazola-Camacho, Mauricio Domínguez-Castro, Ismael Mancilla‐Herrera, Ricardo Figuero-Damián, Margarita López‐Martínez, Elías Sánchez-Serrano   +7 more
openalex   +2 more sources

Sustained HIV Suppression With Co-formulated Tenofovir Disoproxil Fumarate/Lamivudine/Dolutegravir in a Person With Transmitted Dolutegravir Resistance and Pretreatment Resistance to Lamivudine: a Case Report From HPTN 083. [PDF]

Open Forum Infect Dis
Moore HP, Fogel JM, Marzinke MA, Halvas EK, Parikh UM, Mellors JW, Penrose KJ, Seisa M, Petropoulos C, Price AL, Moser A, Wang Z, McCauley M, Valencia-Huamaní J, Rinehart AR, Rooney JF, Soto-Torres L, Grinsztejn B, Landovitz RJ, Eshleman SH.   +19 more
europepmc   +1 more source

Prevalence and correlates of hyperbilirubinemia among people living with HIV (PLHIV) receiving atazanavir boosted with ritonavir (ATV/r). [PDF]

BMC Gastroenterol
Farrokhi H, Shahmohamadi E, Pashaei A, Emadi Koochak H, Nooralioghli Parikhani S, Fathi Amrollah M, Mirzapour P, Dehghan Manshadi SA, SeyedAlinaghi S, Hackett D.   +9 more
europepmc   +1 more source

Lamivudine and tenofovir pharmacokinetic variability in people with HIV in Papua New Guinea. [PDF]

Br J Clin Pharmacol
Andriguetti NB, Barratt DT, Tucci J, Pumuye P, Somogyi AA.   +4 more
europepmc   +1 more source

No changes in weight, body composition or metabolic parameters after the switch to dolutegravir and lamivudine compared to continued treatment with dolutegravir, abacavir and lamivudine for virologically suppressed HIV infection (The AVERTAS trial). [PDF]

BMC Infect Dis
Heje KB, Lindhardt MS, Meddis A, Knudsen A, Kronborg G, Weis N, Lebech AM, Kirk O, Helweg-Larsen J, Helms M, Fischer CP, Hansen AE, Møller S, Siebner HR, Hove JD, Gerstoft J, Benfield T.   +16 more
europepmc   +1 more source

Distribution and efficacy of dolutegravir-based regimens in the main HIV outpatient care in Caracas, Venezuela. [PDF]

AIDS Res Ther
Alvarado-Bruzual MF, Mendoza-Merlo VA, Martinez-Torres JA, Guerra-Reyes LJ, Guevara RN, Carballo M, Redondo MC, Landaeta ME, Forero-Peña DA.   +8 more
europepmc   +1 more source

Prevalence of Diabetes Mellitus Among People Living With HIV and Receiving Antiretroviral Therapy at Muhimbili National Hospital in Tanzania. [PDF]

Cureus
Msuya EV, Kalinga E, Sangu L, Osati EF, Sangeda RZ.   +4 more
europepmc   +1 more source